智通财经APP讯,金斯瑞生物科技(01548)发布公告,公司建议将Probio Technology Limited(“蓬勃生物”,为公司的间接非全资附属公司,负责集团的生物制剂及先进疗法合约研究、开发及生产组织服务)分拆并将其股份在联交所主板独立上市。
就建议分拆而言,公司已根据第15项应用指引向联交所提交申请。于2026年8月14日,上市委员会确认公司可继续推行建议分拆。
智通财经APP讯,金斯瑞生物科技(01548)发布公告,公司建议将Probio Technology Limited(“蓬勃生物”,为公司的间接非全资附属公司,负责集团的生物制剂及先进疗法合约研究、开发及生产组织服务)分拆并将其股份在联交所主板独立上市。
就建议分拆而言,公司已根据第15项应用指引向联交所提交申请。于2026年8月14日,上市委员会确认公司可继续推行建议分拆。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.